Work

Mind the gap in clinical practice guidelines—how I treat CLL patients with unmutated IGHV status

Year: 2025

Type: article

Abstract: Summary The treatment of chronic lymphocytic leukemia has made immense progress in recent years. Nevertheless, different risk constellations persist even with the use of targeted therapies. One of these, unmutated IGHV status, continues to have a prognostic influence. This review discusses the current therapy recommendations and highlights the use of limited therapies and long-term therapies with a particular focus on patients harboring this risk factor.

Source: memo - Magazine of European Medical Oncology

DOI: 10.1007/s12254-025-01035-6

Author: Katharina Prochazka

Institutions: University of Graz, Medical University of Graz, Graz University Hospital

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,790